Subscribe
16 April 2013Americas

Myriad: the oral arguments

On Monday, April 15, the US Supreme Court heard oral arguments on whether genetic material is patent eligible subject matter and in particular, whether Utah-based Myriad Genetics’ patents covering isolated human genes linked to breast and ovarian cancer are valid and enforceable.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
US Supreme Court strikes Myriad blow
13 June 2013   The US Supreme Court has ruled that isolated human DNA is not patent eligible and has struck down patents owned by biotech company Myriad, ending a long-running and controversial case.


Editor's picks

Americas
Fed Circ ruling on Wuhan import ban shakes up economic prong analysis
11 February 2025

Editor's picks

Americas
Fed Circ ruling on Wuhan import ban shakes up economic prong analysis
11 February 2025
Careers
Bristows appoints Irish patent attorney to boost UPC representation
4 February 2025
Americas
New national rankings recognise top US patent firms and lawyers
4 February 2025
Europe
UK court upholds EU SPC precedent, rejecting MSD’s appeal
30 January 2025
Americas
ADCs, TCR, and multimodal AI: Transformative trends in 2025
23 January 2025
Americas
Trump nixes Biden’s Executive Order on drug pricing
21 January 2025

More on this story

Americas
US Supreme Court strikes Myriad blow
13 June 2013   The US Supreme Court has ruled that isolated human DNA is not patent eligible and has struck down patents owned by biotech company Myriad, ending a long-running and controversial case.

More on this story

Americas
US Supreme Court strikes Myriad blow
13 June 2013   The US Supreme Court has ruled that isolated human DNA is not patent eligible and has struck down patents owned by biotech company Myriad, ending a long-running and controversial case.

More features

'A very good decision’: Patent industry welcomes UPC in-house reps update
Make a difference: Cast your vote in IP Diversity & Inclusion Awards 2025
Courtroom report: Regeneron’s $6bn biosimilar battle against Mylan
Fed Circ ruling on Wuhan import ban shakes up economic prong analysis
Meet the new hire driving Bristows’ UPC strategy
Morgan Lewis expands team with five-partner hire
Fed Circ raises ‘gamesmanship’ fears in rare patent term dispute
Whoop faces suit over tech in health tracker watch